ClinicalTrials.gg
RecruitingNCT07033416ABMCocaineUpdated Dec 24, 2025

A Trial Of Approach Bias Modification Training During Treatment For Cocaine Use Disorder

An interventional study of Approach Bias Modification and Treatment as usual in Training for Cocaine Use Disorder, sponsored by ASST Fatebenefratelli Sacco. Recruiting at 1 site in Italy. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-12-24.

Sponsored by ASST Fatebenefratelli Sacco · Not applicable, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
60
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Study summary

The goal of this clinical trial is to investigate if the intervention "Approach Bias Modification" (ABM) can low cocaine craving in people with Cocaine Use Disorder (CUD).

The main question this clinical trial aims to answer is how many days participants can be in abstinence from cocaine after 4 ABM sessions.

ABM is a computerised training aiming to train the participants to:

  • avoid drug-related images by pushing a joystick which causes the image to disappear;
  • approach positive images by pulling a joystick which causes the image to expand.

Researchers will compare participants treated with ABM to those who receive Treatment As Usual (TAU) condition to see if ABM training for CUD is more effective in increasing the number of abstinent days.

  • Participants will attend 1 ABM session per week for a total of 4 sessions, each lasting 15 minutes.
  • Both cocaine and non-cocaine positive images relative to the subjective values or interests (i.e. effects, sport, music, nature, work, etc.) are presented to the participant, in portrait or landscape orientation.
  • Participants are instructed to push the joystick if the image is portrait-oriented (cocaine-related images) or to pull the joystick if it is landscape-oriented (positive images).
  • At 1 and 3-month-follow up, participants will complete self-report questionnaires to measure abstinence days and describe the effect of ABM on cocaine use, dependence symptoms, and approach bias.
02

Conditions studied

  • Training for Cocaine Use Disorder

Keywords

  • APPROACH BIAS MODIFICATION
  • RCT
  • COCAINE USE DISORDER
03

In context

Lead sponsor

ASST Fatebenefratelli Sacco is the lead sponsor of 38 studies on the registry; 12 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • participants must be aged at least 18 years;
  • current DSM 5 TR Cocaine Use Disorder;
  • sufficient Italian language proficiency to understand the participant information sheet, questionnaires and intervention task instructions;
  • signed Consent form.

Exclusion criteria

Exclusion Criteria:

Participants are excluded from participating if they have:

  • neurological disorder or injury or brain trauma involving loss of consciousness for longer than 30 minutes;
  • severe psychiatric disorder, as evaluated by clinical judgement;
  • antipsychotic medication;
  • intellectual disability;
  • missing ;
  • planned absence from attendance through the training period (one month).
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Outcomes assessor)
Enrollment
60 participants (estimated)

Study arms

  • Experimental
    ABM+TAU

    Participants treated with the experimental training Approach Bias Modification (ABM), and the usual treatment (Treatment As Usual, TAU).

    Behavioral: Approach Bias Modification · Behavioral: Treatment as usual

  • Active comparator
    TAU

    Participants treated with the usual treatment (Treatment As Usual, TAU).

    Behavioral: Treatment as usual

Interventions

  • BehavioralApproach Bias Modification

    ABM is a computerised training aiming to train the participants to avoid drug-related images (by pushing a joystick which causes the image to disappear) and approach positive images (by pulling a joystick which causes the image to expand). Each training session lasts 15 minutes and it takes place once per week for 4 weeks.

  • BehavioralTreatment as usual

    Participants receiving TAU are not trained to avoid drug-related images and approach positive images.

06

What researchers measure

Primary outcomes

  1. Abstinence days from cocaine after 4 Approach Bias Modification (ABM) training sessions

    Abstinence days from cocaine measured by urine analysis and a self-report questionnaire (Timeline Follow-Back, TLFB) measuring frequency and quantity of cocaine use and route of administration.

    Time frame: Urine analysis from enrollment to the end of treatment twice a week,in the first three weeks. TLFB at 1 and 3 months after the end of training.

Secondary outcomes

  1. Operationalisation of continuous abstinence in participants trained with ABM, relative to TAU.

    Operationalisation of continuous abstinence is assessed by urine analysis and self-report questionnaires: • Craving Experience Questionnaire (CEQ): two 10-item scales, one measuring the frequency of cravings over a defined time period, and the other assessing the strength of the strongest cravings during this period.

    Time frame: at 1 and 3 months after the end of training.

  2. Operationalisation of continuous abstinence in participants trained with ABM, relative to TAU

    Severity of Dependence Scale (SDS): a continuous measure of psychological dependence on cocaine. A score of zero is assigned to no cocaine use during the past month.

    Time frame: at 1 and 3 months after the end of training

  3. Operationalisation of continuous abstinence in participants trained with ABM, relative to TAU.

    Operationalisation of continuous abstinence is assessed by urine analysis and self-report questionnaires: Timeline Follow-back (TLFB): a measure of frequency and quantity of cocaine use and route of administration

    Time frame: at 1 and 3 months after the end of training

  4. Operationalisation of continuous abstinence in participants trained with ABM, relative to TAU.

    Operationalisation of continuous abstinence is assessed by urine analysis and self-report questionnaires: Modified Stroop Task for Addiction (MST): a 0-to-100 scale measuring attention regulation and suppression of interference due to semantic incongruence or salience of addiction-related stimuli.

    Time frame: at 1 month after the end of training

  5. Operationalisation of continuous abstinence in participants trained with ABM, relative to TAU.

    Operationalisation of continuous abstinence is assessed by urine analysis and self-report questionnaires: Modified Go/No-go Task for Addiction (MGNT): a measure of suppression of pre-potent responses and control of attention bias for salient stimuli associated with addiction-related.

    Time frame: at 1 month after the end of training

07

Study locations

1 of 1 sites recruiting
  • Struttura Semplice Servizio Dipendenze
    Milan, Milano 20131, Italy
    Recruiting
08

References and documents

Individual participant data

Plan to share: No — At present ethics has not approved the sharing of IPD with researchers outside of the investigator team

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Start is estimated for Mar 2026; primary completion for Oct 2026, 7 months later.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 5, 2025
First posted
Jun 24, 2025
StartEst.
Mar 31, 2026
Primary completionEst.
Oct 31, 2026
CompletionEst.
Oct 31, 2026
Last update
Dec 24, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 24, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07033416
Lead sponsor
ASST Fatebenefratelli Sacco
Collaborators
Monash University
Responsible party
Doriana Losasso, Psych (Principal Investigator, ASST Fatebenefratelli Sacco) — Principal investigator
First posted
Jun 24, 2025
Start date
Mar 31, 2026 (estimated)
Primary completion
Oct 31, 2026 (estimated)
Completion
Oct 31, 2026 (estimated)
Last update
Dec 24, 2025

Study contacts

Stefania Cheli, PhD
Contact
stefania.cheli@asst-fbf-sacco.it
+390250319643
Doriana Losasso
principal investigator · ASST Fatebenefratelli Sacco

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion